Global Eftrenonacog Alfa Market Growth 2025-2031

The global Eftrenonacog Alfa market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.

Eftrenonacog alfa is a long-acting recombinant fusion protein used in the treatment of hemophilia B. It is comprised of a single molecule of human factor IX (FIX) covalently linked to the constant region (Fc) domain of human IgG1 via recombinant DNA technology in a human embryonic kidney cell line (HEK293H).

• The presence of the Fc domain extends the terminal half-life which confers clinical benefits of prolonged therapeutic efficacy, less frequent intravenous injections for patient convenience and improved adherence to prophylaxis.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, growing at a CAGR of 5% during the next six years.

The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases, and the expansion of emerging markets.

1. The medical devices market plays a significant role in the healthcare industry.
2. The market is driven by several factors, including increased demand for advanced healthcare services globally and advancements in medical technology.

Segmentation by Type:

• 250IU
• 500IU
• 1000IU
• 2000IU

Segmentation by Application:

• Hemophilia
• Surgical Bleeding
• Long-term Bleeding Prevention

This report also splits the market by region:

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

The companies that are profiled have been selected based on inputs gathered from primary experts:

• Vetter Pharma-Fertigung GmbH & Co.KG
• Sanofi Aventis
• Bioverativ Therapeutics Inc.
• Biogen Inc
• SWEDISH ORPHAN BIOVITRUM AB

Key Questions Addressed in this Report:

1. What is the 10-year outlook for the global Eftrenonacog Alfa market?
2. What factors are driving Eftrenonacog Alfa market growth, globally and by region?
3. Which technologies are poised for the fastest growth by market and region?
4. How do Eftrenonacog Alfa market opportunities vary by end market size?
5. How does Eftrenonacog Alfa break out by Type, by Application?